曲美他嗪治疗冠心病并糖尿病伴慢性心衰临床研究

目的探讨曲美他嗪治疗冠心病并糖尿病伴慢性心衰的临床疗效。方法选择医院2013年7月至2017年8月收治的冠心病并糖尿病伴慢性心衰患者160例,按随机数字表法分为治疗组和对照组,各80例。两组患者均给予常规治疗,治疗组患者加用曲美他嗪治疗。两组均治疗48周。结果治疗后,治疗组患者左室舒张末期内径(LVEDd)和左室收缩末期内径(LVESd)较对照组明显缩小(P<0.05),左室射血分数(LVEF)较对照组明显升高(P<0.01);治疗组患者肌钙蛋白T(cTnT)、脑钠肽(BNP)、C反应蛋白(CRP)、糖化血红蛋白(HbA1C)均低于对照组(P<0.01),高密度脂蛋白(HDL)明显高于对照组(P<0.05)。结论曲美他嗪治疗冠心病合并糖尿病伴慢性心衰安全有效。

Objective To investigate the clinical efficacy of trimetazidine in the treatment of coronary heart disease with diabetes mellitus and chronic heart failure.Methods Totally 160 patients with coronary heart disease with diabetes mellitus and chronic heart failure admitted to our hospital from July 2013 to August 2017 were selected and randomly divided into treatment group and control group,80 cases in each group.Both groups were given routine treatment,on this basis,the treatment group was treated with trimetazidine.Both groups were treated for 48 weeks.Results After treatment,the left ventricular enddiastolic diameter(LVEDd) and left ventricular end-systolic diameter(LVESd) in the treatment group were significantly smaller than those in the control group(P<0.05),the left ventricular ejection fraction(LVEF) was significantly higher than those in the control group(P<0.01),the troponin T(cTnT),brain natriuretic peptide(BNP),C-reactive protein(CRP),glycated hemoglobin (HbA1C),low density lipoprotein(LDL) in the treatment group were significantly higher than those in the control group(P<0.01),while the high density lipoprotein(HDL) in the treatment group was significantly higher than that in the control group(P<0.05).Conclusion Trimetazidine is safe and effective in the treatment of coronary heart disease with diabetes mellitus and chronic heart failure.